In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (0.4-, 2-, and 6-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50
Expiration Date 02/11/2028 00:00:00 UPC 850049609425 Ingredients Non-GMO sunflower oil & lecithin (containing phosphatidylcholine
Abstract: Depeint, F., Bruce, W
The use of a different cell type may require modification of the model, given the particular physiological characteristics of each endothelial cell type
Additionally, key safety considerations include avoiding use during pregnancy and breastfeeding, and monitoring for signs of pancreatitis or gallbladder disease
By modulating these central pathways, the peptide enhances sexual desire and responsiveness, distinguishing it from therapies that focus exclusively on vascular mechanisms